Honokiol Ameliorates LPS/D-GalN-Induced Acute Liver Failure via Activation of SIRT3/AMPK and Keap1/Nrf2/HO-1 Signaling and Inhibition of the NF-κB/NLRP3 Inflammasome Axis
Abstract
Share and Cite
Alhussaini, A.F.; Elshal, M.; Hazem, S.H. Honokiol Ameliorates LPS/D-GalN-Induced Acute Liver Failure via Activation of SIRT3/AMPK and Keap1/Nrf2/HO-1 Signaling and Inhibition of the NF-κB/NLRP3 Inflammasome Axis. Pharmaceuticals 2026, 19, 909. https://doi.org/10.3390/ph19060909
Alhussaini AF, Elshal M, Hazem SH. Honokiol Ameliorates LPS/D-GalN-Induced Acute Liver Failure via Activation of SIRT3/AMPK and Keap1/Nrf2/HO-1 Signaling and Inhibition of the NF-κB/NLRP3 Inflammasome Axis. Pharmaceuticals. 2026; 19(6):909. https://doi.org/10.3390/ph19060909
Chicago/Turabian StyleAlhussaini, Abdulaziz F., Mahmoud Elshal, and Sara H. Hazem. 2026. "Honokiol Ameliorates LPS/D-GalN-Induced Acute Liver Failure via Activation of SIRT3/AMPK and Keap1/Nrf2/HO-1 Signaling and Inhibition of the NF-κB/NLRP3 Inflammasome Axis" Pharmaceuticals 19, no. 6: 909. https://doi.org/10.3390/ph19060909
APA StyleAlhussaini, A. F., Elshal, M., & Hazem, S. H. (2026). Honokiol Ameliorates LPS/D-GalN-Induced Acute Liver Failure via Activation of SIRT3/AMPK and Keap1/Nrf2/HO-1 Signaling and Inhibition of the NF-κB/NLRP3 Inflammasome Axis. Pharmaceuticals, 19(6), 909. https://doi.org/10.3390/ph19060909

